The use of dendritic cells in cancer immunotherapy

Nencioni, Alessio; Grünebach, Frank; Schmidt, Susanne; Müller, Martin; Boy, Davide; Patrone, Franco; Ballestrero, Alberto; Brossart, Peter

doi:10.1016/j.critrevonc.2007.10.002

Cited by 87 publications

(59 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also underscore the desperate need for a safe, effective, and practical HIV immunotherapy. Human clinical trials evaluating dendritic cell (DC) immunotherapy are ongoing (22) and have already shown some immunogenic efficacy in the treatment of certain cancers (17,23,28,32) and simian immunodeficiency virus (SIV) infection of macaques (13,20) and in early clinical trials of HIV immunotherapy (19). DC-based immunotherapies generally rely on the induction of high levels of T-cell immunity.…”

mentioning

confidence: 99%

Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy

Mason

Alcântara

Peut

et al. 2009

J Virol

View full text Add to dashboard Cite

Practical immunotherapies for human immunodeficiency virus infection are needed. We evaluated inactivated simian immunodeficiency virus (SIV) pulsed onto fresh peripheral blood mononuclear cells in 12 pigtail macaques with chronic SIV mac251 infection for T-cell immunogenicity in a randomized cross-over design study. The immunotherapy was safe and convincingly induced high levels of SIV-specific CD4 ؉ T-cell responses (mean, 5.9% ؎ 1.3% of all CD4 ؉ T cells) and to a lesser extent SIV-specific CD8 ؉ T-cell responses (mean, 0.7% ؎ 0.4%). Responses were primarily directed toward Gag and less frequently toward Env but not Pol or regulatory/accessory SIV proteins. T-cell responses against Gag were generally broad and polyfunctional, with a mean of 2.7 CD4 ؉ T-cell epitopes mapped per animal and more than half of the SIV Gag-specific CD4 ؉ T cells expressing three or more effector molecules. The immunogenicity was comparable to that found in previous studies of peptide-pulsed blood cells. Despite the high-level immunogenicity, no reduction in viral load was observed in the chronically viremic macaques. This contrasts with our studies of immunization with peptide-pulsed blood cells during early SIV infection in macaques. Future studies of inactivated virus-pulsed blood cell immunotherapy during early infection of patients receiving antiretroviral therapy are warranted.

show abstract

mentioning

confidence: 99%

Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy

Mason

Alcântara

Peut

et al. 2009

J Virol

View full text Add to dashboard Cite

show abstract

“…[14][15][16] Crucially, dendritic cells strongly express the costimulatory molecules required to induce primary immunity. 15 Ex vivo studies have demonstrated the ability of dendritic cells to interact with foreign antigens and present these to na€ ıve CD4C T cells, generating a clonal expansion of effector T cells.…”

Section: Dendritic Cell Vaccinesmentioning

confidence: 99%

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

Pyzer

Avigan

Rosenblatt³

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Such vaccines follow two purposes, namely priming antigen-specific T cells and reprogramming memory T cells by transforming them from the immunosuppressive to the immunostimulating and cytotoxic phenotype. Dendritic cells (DCs) are very potent antigen presenting cells and thus essential in generation of immune responses, and they therefore represent valuable targets and vectors for cancer vaccination [280][281][282][283][284][285][286][287][288][289][290][291][292][293].…”

Section: Neutrophilsmentioning

confidence: 99%

A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

Schwendener¹,

Mete²

2013

Frontiers in Clinical Drug Research - Anti-Cancer Agents

View full text Add to dashboard Cite

Solid tumors grow within a complex microenvironment composed of diverse cell types such as fibroblasts, endothelial cells, mast cells, macrophages and immune cells that are attracted by tumor cell derived factors and embedded in an extracellular matrix. Molecular and cellular interactions between epithelial cells and cells surrounding the tumor stroma promote growth, invasion and spread of tumors. To delay or impede tumor growth, the tumor microenvironment (TME) is increasingly being explored as a potential therapeutic target for which novel strategies are developed. lt;/pgt;lt;pgt; This article reviews how key interactions between tumor cells and surrounding mesenchymal and immune cells in the TME can promote tumor progression and it highlights cellular and molecular elements that might represent novel therapeutic targets. Special emphasis is given on therapies targeted towards tumor-associated macrophages. As main class of drugs the bisphosphonates are covered with their properties to repolarize a pro-tumorigenic, immunosuppressive environment to a tumor growth inhibiting and immunocompetent microenvironment. Properties and advantages of liposome-encapsulated bisphosphonates as macrophage depleting or modulating agents as well as the latest developments towards clinical applications of compounds targeting cellular and molecular components of the TME are described and reviewed. This article reviews how key interactions between tumor cells and surrounding mesenchymal and immune cells in the TME can promote tumor progression and it highlights cellular and molecular elements that might represent novel therapeutic targets. Special emphasis is given on therapies targeted towards tumor-associated macrophages. As main class of drugs the bisphosphonates are covered with their properties to repolarize a pro-tumorigenic, immunosuppressive environment to a tumor growth inhibiting and immunocompetent microenvironment. Properties and advantages of liposome-encapsulated bisphosphonates as macrophage depleting or modulating agents as well as the latest developments towards clinical applications of compounds targeting cellular and molecular components of the TME are described and reviewed.

show abstract

The use of dendritic cells in cancer immunotherapy

Cited by 87 publications

References 66 publications

Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy

Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

A New Approach to Cancer Therapy: The Tumor Microenvironment as Target

Contact Info

Product

Resources

About